EGFR and neoplasm: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are currently the most effective treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations and can result in marked tumor shrinkage.